Jula MD - Travere Therapeutics Chief Officer
| TVTX Stock | USD 18.18 0.07 0.38% |
Executive
Jula MD is Chief Officer of Travere Therapeutics
| Age | 49 |
| Address | 3611 Valley Centre Drive, San Diego, CA, United States, 92130 |
| Phone | 888 969 7879 |
| Web | https://www.travere.com |
Travere Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2614) % which means that it has lost $0.2614 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.7994) %, meaning that it created substantial loss on money invested by shareholders. Travere Therapeutics' management efficiency ratios could be used to measure how well Travere Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.17 in 2024. Return On Capital Employed is likely to rise to -0.59 in 2024. At this time, Travere Therapeutics' Non Currrent Assets Other are fairly stable compared to the past year. Other Current Assets is likely to rise to about 20.3 M in 2024, whereas Total Assets are likely to drop slightly above 461.7 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Matthew JD | Protagonist Therapeutics | 53 | |
| Jan Smith | Revolution Medicines | N/A | |
| Henry Pelish | Nuvalent | N/A | |
| Steven Gavel | Legend Biotech Corp | N/A | |
| Lukas MD | Apellis Pharmaceuticals | 53 | |
| FACP MD | Protagonist Therapeutics | 65 | |
| Steven JD | Cytokinetics | 65 | |
| Stuart Naylor | MeiraGTx Holdings PLC | 61 | |
| Perrin BS | Nuvalent | N/A | |
| Michael White | Ideaya Biosciences | 58 | |
| Jason Hoitt | Stoke Therapeutics | 46 | |
| David Acheson | Apellis Pharmaceuticals | N/A | |
| James JD | Legend Biotech Corp | N/A | |
| Stuart MD | Cytokinetics | N/A | |
| Alastair Leighton | MeiraGTx Holdings PLC | N/A | |
| Guowei Fang | Legend Biotech Corp | N/A | |
| Sheila MD | Ventyx Biosciences | 54 | |
| Matthew Gosling | Protagonist Therapeutics | 53 | |
| Andrew Callos | Cytokinetics | 55 | |
| Scott Jordan | Cytokinetics | N/A | |
| Deborah Wong | Legend Biotech Corp | N/A | |
Management Performance
| Return On Equity | -2.8 | ||||
| Return On Asset | -0.26 |
Travere Therapeutics Leadership Team
Elected by the shareholders, the Travere Therapeutics' board of directors comprises two types of representatives: Travere Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Travere. The board's role is to monitor Travere Therapeutics' management team and ensure that shareholders' interests are well served. Travere Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Travere Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| William Rote, Senior Development | ||
| Elizabeth JD, General VP | ||
| CFA CFA, Chief Officer | ||
| Angela Giannantonio, Senior Resources | ||
| Jula MD, Chief Officer | ||
| Casey Logan, Chief Officer | ||
| Elizabeth Reed, General VP | ||
| Sandra Calvin, Corporate SVP | ||
| Nivi Nehra, Vice Relations | ||
| Christopher CFA, Chief Officer | ||
| Eric Dube, CEO President | ||
| Charlotte Smith, Senior Affairs | ||
| Noah MD, Ex Advisor | ||
| Naomi Eichenbaum, Vice Relations | ||
| Peter Heerma, Chief Officer |
Travere Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Travere Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.8 | ||||
| Return On Asset | -0.26 | ||||
| Profit Margin | (1.73) % | ||||
| Operating Margin | (0.89) % | ||||
| Current Valuation | 1.71 B | ||||
| Shares Outstanding | 87.03 M | ||||
| Shares Owned By Insiders | 0.65 % | ||||
| Shares Owned By Institutions | 98.59 % | ||||
| Number Of Shares Shorted | 7.99 M | ||||
| Price To Book | 76.10 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Travere Stock Analysis
When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.